BACKGROUND: Evidence has suggested that immunosuppressive drugs impact ischemia-reperfusion injury. AIMS: The purpose of the present study was to evaluate the effect of sirolimus on hepatic injury and regeneration in a rat reduced-size liver ischemia-reperfusion model. METHODS: Using a newly developed rat reduced-size liver ischemia-reperfusion injury model, the effects of sirolimus were evaluated by assessing liver cell apoptosis and aspartate aminotransferase, myeloperoxidase, and malondialdehyde levels. In addition, liver regeneration after sirolimus treatment was evaluated by measuring liver weight resumption and by the histological examination of bromodeoxyuridine and proliferating cell nuclear antigen expression. RESULTS: Sirolimus significantly decreased liver cell apoptosis as well as tissue myeloperoxidase and malondialdehyde levels, but impaired postischemic liver regeneration. Ischemia-reperfusion-induced elevation of aspartate aminotransferase serum levels was significantly decreased by sirolimus. CONCLUSIONS: Despite an impairment of postischemic liver proliferation, sirolimus demonstrated beneficial amelioration of ischemia-reperfusion-induced liver injury in a reduced-size liver model in rats.
BACKGROUND: Evidence has suggested that immunosuppressive drugs impact ischemia-reperfusion injury. AIMS: The purpose of the present study was to evaluate the effect of sirolimus on hepatic injury and regeneration in a rat reduced-size liver ischemia-reperfusion model. METHODS: Using a newly developed rat reduced-size liver ischemia-reperfusion injury model, the effects of sirolimus were evaluated by assessing liver cell apoptosis and aspartate aminotransferase, myeloperoxidase, and malondialdehyde levels. In addition, liver regeneration after sirolimus treatment was evaluated by measuring liver weight resumption and by the histological examination of bromodeoxyuridine and proliferating cell nuclear antigen expression. RESULTS:Sirolimus significantly decreased liver cell apoptosis as well as tissue myeloperoxidase and malondialdehyde levels, but impaired postischemic liver regeneration. Ischemia-reperfusion-induced elevation of aspartate aminotransferase serum levels was significantly decreased by sirolimus. CONCLUSIONS: Despite an impairment of postischemic liver proliferation, sirolimus demonstrated beneficial amelioration of ischemia-reperfusion-induced liver injury in a reduced-size liver model in rats.
Authors: J A Goss; H Yersiz; C R Shackleton; P Seu; C V Smith; J S Markowitz; D G Farmer; R M Ghobrial; J F Markmann; W S Arnaout; D K Imagawa; S D Colquhoun; M H Fraiman; S V McDiarmid; R W Busuttil Journal: Transplantation Date: 1997-09-27 Impact factor: 4.939
Authors: Y Liu; M Gorospe; G C Kokkonen; M O Boluyt; A Younes; Y D Mock; X Wang; G S Roth; N J Holbrook Journal: Exp Cell Res Date: 1998-04-10 Impact factor: 3.905
Authors: Marc de Perrot; Kevin Young; Yumiko Imai; Mingyao Liu; Thomas K Waddell; Stefan Fischer; Li Zhang; Shaf Keshavjee Journal: J Immunol Date: 2003-11-15 Impact factor: 5.422
Authors: Giovanni Stallone; Salvatore Di Paolo; Antonio Schena; Barbara Infante; Michele Battaglia; Pasquale Ditonno; Loreto Gesualdo; Giuseppe Grandaliano; Francesco Paolo Schena Journal: J Am Soc Nephrol Date: 2004-01 Impact factor: 10.121
Authors: Suomi Mg Fouraschen; Petra E de Ruiter; Jaap Kwekkeboom; Ron Wf de Bruin; Geert Kazemier; Herold J Metselaar; Hugo W Tilanus; Luc Jw van der Laan; Jeroen de Jonge Journal: World J Transplant Date: 2013-09-24
Authors: Felix Oldhafer; Eva-Maria Wittauer; Christine S Falk; Daphne E DeTemple; Oliver Beetz; Kai Timrott; Moritz Kleine; Florian W R Vondran Journal: Ann Transplant Date: 2019-08-13 Impact factor: 1.530